Xencor Inc
XNCR7.910USD
-0.070-0.88%
交易中 （美東）報價延遲15分鐘
562.69M總市值
虧損本益比TTM
關於 Xencor Inc 公司
Xencor, Inc. 是一家臨牀階段的生物製藥公司，致力於開發用於治療癌症和其他嚴重疾病的工程抗體。採用其 XmAb 技術設計的 20 多種候選藥物正在臨牀開發中，三種 XmAb 藥物由合作伙伴銷售。其 XmAb 工程技術可以對蛋白質結構進行微小改變，從而產生新的治療作用機制。其全資開發的候選藥物包括 Vudalimab、XmAb819、XmAb808 和 XmAb541。與合作伙伴共同開發的候選藥物包括 Plamotamab。合作伙伴推進的候選藥物包括 Xaluritamig (AMG 509)、ASP2138、JNJ-9401、JNJ-1493 和 Novartis XmAb 未公開的抗體候選藥物。其處於臨牀開發中的細胞因子藥物候選藥物包括 fbalropendekin alfa (XmAb306/RG6323)、XmAb564 和 XmAb662。該公司其他臨牀階段候選藥物包括 Obexelimab、AIMab7195 (XmAb7195) 和 Xpro1595。Vudalimab 是一種針對 PD-1 和 CTLA-4 的雙特異性抗體。
公司簡介
公司代碼XNCR
公司名稱Xencor Inc
上市日期Dec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
員工數量250
證券類型Ordinary Share
年結日Dec 03
公司地址465 N. Halstead St.
城市PASADENA
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編91107
電話16263055900
網址https://xencor.com/
公司代碼XNCR
上市日期Dec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
15.09%
PRIMECAP Management Company
13.71%
The Vanguard Group, Inc.
12.12%
EcoR1 Capital, LLC
8.63%
T. Rowe Price Associates, Inc.
5.38%
Other
45.06%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
15.09%
PRIMECAP Management Company
13.71%
The Vanguard Group, Inc.
12.12%
EcoR1 Capital, LLC
8.63%
T. Rowe Price Associates, Inc.
5.38%
Other
45.06%
股東類型
持股股東
佔比
Investment Advisor
59.58%
Investment Advisor/Hedge Fund
31.25%
Hedge Fund
15.77%
Research Firm
2.93%
Venture Capital
1.94%
Individual Investor
1.32%
Pension Fund
1.03%
Bank and Trust
0.36%
Sovereign Wealth Fund
0.25%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
437
81.46M
114.46%
-1.77M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
2023Q3
417
65.14M
107.37%
-1.33M
2023Q2
422
64.91M
107.12%
-2.55M
2023Q1
418
65.89M
109.12%
+515.07K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
10.74M
15.09%
-230.83K
-2.10%
Mar 31, 2025
PRIMECAP Management Company
9.76M
13.71%
+776.58K
+8.64%
Mar 31, 2025
The Vanguard Group, Inc.
7.88M
11.08%
-118.90K
-1.49%
Mar 31, 2025
EcoR1 Capital, LLC
6.14M
8.63%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.83M
5.38%
-108.25K
-2.75%
Mar 31, 2025
State Street Global Advisors (US)
3.68M
5.18%
+482.80K
+15.08%
Mar 31, 2025
BVF Partners L.P.
2.74M
3.85%
+451.38K
+19.72%
Mar 31, 2025
TCG Crossover Management, LLC
2.45M
3.45%
--
--
Mar 31, 2025
RTW Investments L.P.
2.40M
3.38%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.74M
2.44%
+235.86K
+15.71%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Invesco S&P SmallCap Health Care ETF
0.4%
ALPS Medical Breakthroughs ETF
0.38%
SPDR S&P Biotech ETF
0.18%
Inspire Small/Mid Cap ESG ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.06%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.21%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.75%
Invesco NASDAQ Future Gen 200 ETF
佔比0.44%
Invesco S&P SmallCap Health Care ETF
佔比0.4%
ALPS Medical Breakthroughs ETF
佔比0.38%
SPDR S&P Biotech ETF
佔比0.18%
Inspire Small/Mid Cap ESG ETF
佔比0.14%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.1%
SPDR SSGA US Small Cap Low Volatility Index ETF
佔比0.08%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
